Literature DB >> 12498387

Mechanisms involved in the differential bone marrow homing of CD45 subsets in 5T murine models of myeloma.

Kewal Asosingh1, Eline Menu, Els Van Valckenborgh, Isabelle Vande Broek, Ivan Van Riet, Ben Van Camp, Karin Vanderkerken.   

Abstract

Multiple myeloma (MM) is an incurable plasma cell cancer, localized in the bone marrow (BM). The mechanisms used by these cells to (re-)enter this organ remain largely unknown. Recently, we reported that both CD45+ and CD45- myeloma cells home to the BM and induce myeloma disease. In this work, we investigated the underlying mechanisms involved in the homing of CD45+ and CD45- myeloma cells in the experimental 5T2MM and 5T33MM murine models. In vivo tracing of flow cytometric sorted and radioactively labeled CD45 subsets revealed a reduced homing of the CD45- 5TMM cells to the BM as compared to the CD45+ 5TMM cells. Migration assays demonstrated an impaired chemotaxis towards BM endothelial cell conditioned medium, BM stromal cell conditioned medium and towards the basement membrane component laminin-1 of the CD45- 5TMM cells compared to the CD45+ subset. Matrix metalloproteinase-9 (MMP-9) and urokinase type plasminogen activator (uPA) are key extracellular matrix proteases involved in the invasion of cancer cells. Inhibitor and antibody blocking experiments demonstrated the involvement of both in the invasion of the 5TMM cells. CD45- 5TMM cells had a low secretion of MMP-9 and (for the non-aggressive line 5T2MM only) a low cell surface expression of uPA receptor, as revealed by gelatin zymography and flow cytometric analysis, respectively. Accordingly, the synthetic basement membrane invasive capacity of the CD45- 5TMM subpopulations was also impaired. Our results indicate that CD45+ and CD45- 5T myeloma cells have a differential BM homing attributable to differential migratory and invasive capacities.

Entities:  

Mesh:

Substances:

Year:  2002        PMID: 12498387     DOI: 10.1023/a:1020987830132

Source DB:  PubMed          Journal:  Clin Exp Metastasis        ISSN: 0262-0898            Impact factor:   5.150


  29 in total

Review 1.  The 5TMM series: a useful in vivo mouse model of human multiple myeloma.

Authors:  K Asosingh; J Radl; I Van Riet; B Van Camp; K Vanderkerken
Journal:  Hematol J       Date:  2000

2.  Insulin-like growth factor-1 acts as a chemoattractant factor for 5T2 multiple myeloma cells.

Authors:  K Vanderkerken; K Asosingh; F Braet; I Van Riet; B Van Camp
Journal:  Blood       Date:  1999-01-01       Impact factor: 22.113

Review 3.  Tumor invasion and metastases--role of the extracellular matrix: Rhoads Memorial Award lecture.

Authors:  L A Liotta
Journal:  Cancer Res       Date:  1986-01       Impact factor: 12.701

4.  Tumor gelatinases and invasion inhibited by the green tea flavanol epigallocatechin-3-gallate.

Authors:  S Garbisa; L Sartor; S Biggin; B Salvato; R Benelli; A Albini
Journal:  Cancer       Date:  2001-02-15       Impact factor: 6.860

5.  A unique pathway in the homing of murine multiple myeloma cells: CD44v10 mediates binding to bone marrow endothelium.

Authors:  K Asosingh; U Günthert; H De Raeve; I Van Riet; B Van Camp; K Vanderkerken
Journal:  Cancer Res       Date:  2001-04-01       Impact factor: 12.701

6.  In vivo homing and differentiation characteristics of mature (CD45-) and immature (CD45+) 5T multiple myeloma cells.

Authors:  K Asosingh; H De Raeve; P Croucher; E Goes; I Van Riet; B Van Camp; K Vanderkerken
Journal:  Exp Hematol       Date:  2001-01       Impact factor: 3.084

Review 7.  Lymphocyte homing and homeostasis.

Authors:  E C Butcher; L J Picker
Journal:  Science       Date:  1996-04-05       Impact factor: 47.728

8.  Transition in CD45 isoform expression during differentiation of normal and abnormal B cells.

Authors:  G S Jensen; S Poppema; M J Mant; L M Pilarski
Journal:  Int Immunol       Date:  1989       Impact factor: 4.823

Review 9.  The role of matrix metalloproteinases in tumor angiogenesis and tumor metastasis.

Authors:  A John; G Tuszynski
Journal:  Pathol Oncol Res       Date:  2001       Impact factor: 3.201

Review 10.  Emerging roles for proteinases in cancer.

Authors:  A Noël; C Gilles; K Bajou; L Devy; F Kebers; J M Lewalle; E Maquoi; C Munaut; A Remacle; J M Foidart
Journal:  Invasion Metastasis       Date:  1997
View more
  8 in total

1.  The phenotypic plasticity of myeloma plasma cells as expressed by dedifferentiation into an immature, resilient, and apoptosis-resistant phenotype.

Authors:  Shmuel Yaccoby
Journal:  Clin Cancer Res       Date:  2005-11-01       Impact factor: 12.531

Review 2.  Bone marrow microenvironment in myelomagenesis: its potential role in early diagnosis.

Authors:  Arun Balakumaran; Pamela Gehron Robey; Neal Fedarko; Ola Landgren
Journal:  Expert Rev Mol Diagn       Date:  2010-05       Impact factor: 5.225

3.  Hypermethylation of the Promoter Region of miR-23 Enhances the Metastasis and Proliferation of Multiple Myeloma Cells via the Aberrant Expression of uPA.

Authors:  Qijie Ran; Dehong Xu; Qi Wang; Dongsheng Wang
Journal:  Front Oncol       Date:  2022-05-30       Impact factor: 5.738

4.  Multifunctional role of matrix metalloproteinases in multiple myeloma: a study in the 5T2MM mouse model.

Authors:  Els Van Valckenborgh; Peter I Croucher; Hendrik De Raeve; Chris Carron; Evy De Leenheer; Sylvia Blacher; Laetitia Devy; Agnès Noël; Elke De Bruyne; Kewal Asosingh; Ivan Van Riet; Ben Van Camp; Karin Vanderkerken
Journal:  Am J Pathol       Date:  2004-09       Impact factor: 4.307

Review 5.  Extravasation and homing mechanisms in multiple myeloma.

Authors:  Isabelle Vande Broek; Karin Vanderkerken; Benjamin Van Camp; Ivan Van Riet
Journal:  Clin Exp Metastasis       Date:  2007-10-19       Impact factor: 5.150

6.  The protein tyrosine phosphatase CD45 is required for interleukin 6 signaling in U266 myeloma cells.

Authors:  Qun Zhou; Yuan Yao; Solveig G Ericson
Journal:  Int J Hematol       Date:  2004-01       Impact factor: 2.490

Review 7.  Tumour Dissemination in Multiple Myeloma Disease Progression and Relapse: A Potential Therapeutic Target in High-Risk Myeloma.

Authors:  Mara N Zeissig; Andrew C W Zannettino; Kate Vandyke
Journal:  Cancers (Basel)       Date:  2020-12-04       Impact factor: 6.639

8.  CD45 regulates retention, motility, and numbers of hematopoietic progenitors, and affects osteoclast remodeling of metaphyseal trabecules.

Authors:  Shoham Shivtiel; Orit Kollet; Kfir Lapid; Amir Schajnovitz; Polina Goichberg; Alexander Kalinkovich; Elias Shezen; Melania Tesio; Neta Netzer; Isabelle Petit; Amnon Sharir; Tsvee Lapidot
Journal:  J Exp Med       Date:  2008-09-08       Impact factor: 14.307

  8 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.